



inpharmus

April - June 2026

Inpharmus Quarterly Brief:

Connecting scientific progress with patient impact

The second quarter of 2026 brought together scientific exchange, rare disease awareness, and important conversations about the future of healthcare.

Across Türkiye, Saudi Arabia, Oman, Qatar, Bahrain, Kuwait, and Russia, Inpharmus engaged with healthcare professionals and industry stakeholders to explore a shared challenge: how to translate scientific progress into timely access, informed clinical practice, and better patient outcomes.

KUR-INPHARMUS-102026-01

Media & Healthcare Perspectives

In April, Ali Tansu Demirkale explored the growing role of artificial intelligence and personalized medicine in healthcare, highlighting how technological advances are reshaping clinical decision-making.

Full interview: <https://www.patronlarkulisi.com/ekonomi/yapay-zeka-ve-kisisellestirilmis-tip-ilac-sektorunu-donusturuyor-11025>

Full broadcast (Kanal 3): <https://youtu.be/X-qGUvLLHgc?si=qYp-336HhVD4fgJC>



ALİ TANSU DEMİRKALE
STRATEGIC STAKEHOLDER RELATIONS DIRECTOR

Scientific Engagement: Oncology & Hematology

In April, our teams participated in the 13th Turkish Medical Oncology Congress and the VII. RODOG Oncology Conference in Moscow, contributing to discussions on evolving treatment approaches and clinical challenges.



Advancing Care Beyond Treatment

In April, our team attended the 25th National Pediatric Cancer Congress to follow scientific developments and engage in discussions around pediatric oncology care.



Rare Diseases: Awareness & Early Recognition

In April, Inpharmus participated in the 10th National Pediatric Rheumatology Congress and the 61st Turkish Pediatrics Congress, supporting scientific discussions on rare pediatric rheumatological and immunological conditions.

World Immunology Day also provided an opportunity to raise awareness of primary immunodeficiencies through a collaboration with Prof. İlhan Tezcan.

Featured awareness content:

<https://www.linkedin.com/feed/update/urn:li:activity:7454923440941301762/>



Internal Alignment & Collaboration

Scientific progress also depends on the people and organizational structures that support it.

On April 22, Inpharmus Headquarters held its quarterly G&A meeting, bringing teams together to review organizational progress and operational priorities.

The meeting opened with remarks from CEO İsmet İnce, followed by a review of 2025 performance, first-quarter developments, and expectations for the upcoming quarter presented by Operations Director Mehmet Beyazyürek.

The meeting provided an opportunity to strengthen internal alignment and establish shared priorities for the months ahead.



Media & Healthcare Perspectives

In May, CEO İsmet İnçe addressed the challenges affecting timely access to innovative treatments and discussed Türkiye's potential as a regional center for clinical research.

Full interview: <https://www.aa.com.tr/tr/isdunyasi/saglik/tedavilere-erisimde-gecikmeyi-cok-katmanli-surecler-belirliyor/702077>

Full interview: <https://www.milliyet.com.tr/ekonomi/turkiye-klinik-arastirmalarda-bolgesel-merkez-olabilir-7596897>



Scientific Engagement: Oncology & Hematology

In May, participation in the National Pediatric Hematology Congress and the ASCO Annual Meeting in Chicago provided further opportunities to engage with developments in hematology, oncology research, and patient care.



Pediatric Oncology: Scientific Discussions

During May, scientific discussions were held in Oman, Qatar, and Bahrain, focusing on current clinical approaches and supportive care strategies in pediatric oncology.



Rare Diseases: Awareness & Early Recognition

In May, activities during World Primary Immunodeficiency Week continued this focus. A scientific meeting at the Royal Hospital in Oman addressed ultra-rare inborn errors of immunity and the importance of early recognition and multidisciplinary care, while a meeting supported by Inpharmus in Kuwait focused on primary immunodeficiency disorders.

Across these initiatives, a consistent message emerged: improving disease awareness and clinical recognition is essential to supporting earlier diagnosis and more informed patient care.



Media & Healthcare Perspectives

June brought further perspectives on the industry's future. In an NTV interview, İsmet İnce discussed the impact of geopolitical developments on pharmaceutical supply chains and healthcare systems. Batuhan Özenc, General Manager of Inpharmus Türkiye, also shared perspectives on the company's long-term vision and Türkiye's role in the regional pharmaceutical ecosystem.

Full interview: <https://www.youtube.com/watch?v=ILcxbUzlzSM>

Full interview: <https://euronewsport.com/inpharmus-turkiye-genel-muduru-batuhan-ozenc-hayalimiz-turkiyede-uretim-yapmak/>



Scientific Engagement: Oncology & Hematology

June also featured an oncology-focused scientific meeting in Türkiye, bringing together the Inpharmus Türkiye Oncology team to review scientific evidence and exchange perspectives on clinical practice and patient management.

Together, these activities reflected the importance of continuous learning and evidence-based scientific dialogue in advancing oncology care.



Scientific Engagement: Pediatric Oncology Updates

In June, a scientific summit held in Saudi Arabia brought together international and local experts to discuss comprehensive clinical perspectives alongside multidisciplinary patient care strategies.

An international scientific speaker tour across major institutions in Saudi Arabia further supported knowledge exchange on evolving scientific approaches and current practices in pediatric oncology.

These initiatives reinforced an important principle: advancing scientific collaboration and supporting long-term patient well-being are complementary priorities in complex oncology care.



Looking Ahead

Across three months of scientific engagement, awareness initiatives, and industry discussions, a common question continued to emerge:

How can scientific progress translate into earlier diagnosis, better access, and improved patient outcomes?

Addressing this challenge requires continued collaboration between healthcare professionals, researchers, industry stakeholders, and healthcare systems.

As we move into the second half of 2026, these connections will remain central to our efforts to bring science, knowledge, and patient needs closer together.